Fujitsu Laboratories and Fujitsu have announced the development of molecular simulation technology for drug discovery that can accurately estimate binding affinity, which represents the degree to which proteins that can cause diseases (target proteins) bind to chemical substances that could become candidate drugs.
In the process of drug discovery, there is a demand for accurate prediction of the binding affinity between target proteins and chemical substances, which offers a rough estimate of a drug’s efficacy. Molecular simulation technology has been widely used in the past as a method of predicting binding affinity, calculating the approximate forces that arise between atoms in molecules using Newtonian mechanics.
The problem with this method, however, remains that the low degree accuracy of its estimation of the most important parameters-the degree of torsion at the binding sites. This means that the accuracy of its estimation of the overall binding affinity is also poor.
Now, Fujitsu Laboratories has developed molecular simulation technology that estimates the degree of torsion in a chemical substance, which is directly connected to the predicted binding affinity. The new technology not only takes into account the bonding location where the torsion will occur, but also the impact of neighbouring atoms.
Fujitsu Laboratories evaluated this technology for 190 types of chemical substances, comparing the results with correct results arrived at from first principles calculation and then evaluating the error rate. Upon doing so, it was able to confirm that the error rate in the estimate of the degree of torsion was, on average, one-tenth that of previous technology.
It is anticipated that the use of this new technology in IT-based drug discovery, with its ability to accurately estimate the binding affinity of targeted proteins and chemical substances, offers the potential for groundbreaking new drug discovery efforts that could not be achieved with previous approaches.